

Financial Contracting in Biotech Strategic Alliances

David T. Robinson ^{a,*}

^a*Assistant Professor of Finance and Economics, Graduate School of Business,
Columbia University*

Toby E. Stuart ^b

^b*Fred G. Steingraber-A.T. Kearney Professor of Strategy and Organizations,
University of Chicago*

**Preliminary and Incomplete: Do Not Distribute or
Quote Without Permission**

Abstract

To be completed.

JEL Classification Codes: G30, G34, G39, M13, O39

* Corresponding author. Send correspondence to Uris Hall 414, Columbia University, 3022 Broadway, NY, NY 10027, or e-mail at dtr2001@columbia.edu. We would like to thank Mark Edwards at Recombinant Capital for generously making his data available to us. In addition, we are grateful to George Baker, Bernard Black, Robert Gibbons, Per Strömberg, Andy Wong and participants at the NBER Strategic Alliance pre-conference meeting for helpful comments. Sandhya Persad provided expert research assistance. Any errors are solely our own.

1 Introduction

Strategic alliances and joint ventures are an increasingly common vehicle through which large organizations engage in research and development. For example, survey evidence from the Pharmaceutical Research and Manufacturers of America suggests that roughly 25% of the \$26 billion in US-based, industrially financed, pharmaceutical R&D that occurred in 2000 took place in over 700 collaborative agreements with outside organizations. This fraction has tripled since 1991, and has grown twenty-fold since 1981 (National Science Board, 2000). These numbers only grow in size and importance when one also considers international R&D, as well as corporate and university R&D partially funded through such programs as the Advanced Technology Program (?).

While the financial and strategic importance of these contracts is widely acknowledged, little is known about their precise structure. In this paper, we attempt to fill that void with a detailed, micro-level analysis of strategic alliance and joint venture contracts. We focus on deals written between large pharmaceutical companies and small, often start-up research companies in the biotechnology sector. All of the agreements we analyze were written to conduct genomics-based research, and are distinct from corporate venture capital agreements (see Hellmann (1997)). Instead, in these deals the pharmaceutical firm is a client, sponsoring a research project that the R&D conducts. A common objective in these deals is identifying genetic ‘disease triggers’ that respond to specific chemical compounds, which can then be developed (with considerable uncertainty) into new drugs.

A deeper understanding of strategic alliance contracts achieves several objectives. First, given the hundreds of billions of dollars of industrial R&D that arise from federal, academic, and corporate sources, understanding the organization of corporate R&D is important for purely practical reasons. By

understanding better the key dimensions along which contracts vary, and by understanding how different contract characteristics act as substitutes or complements for one another, we gain insight into the types of mechanisms that are most effective at aligning potentially conflicting incentives in an contractual setting in which complete contracts are inherently difficult to write.

Strategic alliances and joint ventures are thus an ideal empirical setting in which to explore the predictions of a number of recent theoretical models on incomplete contracts and optimal financial contracting. As suggested by models such as Grossman and Hart (1986), Hart and Moore (1990), and Aghion and Tirole (1994), we do observe a complementarity between equity participation and royalty rates (transfer prices): larger royalty rates for the R&D firm coincide with the client taking larger equity positions in the R&D, thus partially internalizing the transfer. However, most of this effect is a result of deals with equity involving higher royalties than deals without equity. We see little complementarity between royalty rates and equity stakes in the subsample that have non-zero equity stakes, which suggests that equity plays a larger role than simply allocating residual cash flow rights.

Nevertheless, the patterns in equity participation that we see in these deals are similar to what Kaplan and Strömberg (2000) show for venture capital contracts: for pre-IPO firms, clients often take equity stakes that involve convertible preferred equity that converts to common stock at IPO. These deals sometimes coincide with board seats, and often involve registration rights and anti-dilution provisions. Preferred equity is much less common among deals involving publicly traded R&D firms.

Our results suggest that much more is at stake in strategic alliance agreements than is suggested by financial contracting theory. This is not to say that our findings are at odds with the predictions of theory; however, many of the concerns addressed in alliance contracts do not appear in bilateral contracting

models with incomplete contracts. For example, how do firms deal with multiple, simultaneous collaborations? Do clients distinguish between the success of a project and the success of the firm undertaking the project? Our preliminary findings suggest that these type of questions seem to be at the heart of many alliance contracts, yet the answers to these questions have not been fully reconciled with existing theory.

This paper is related to a number of other papers that examine financing contracting in various empirical settings. The closest is Kaplan and Strömberg (2000), who examine term sheets from VC investments in order to examine how these agreements correspond to various theories of financial contracting (see also Sahlman (1990)). Likewise, Wong (2001) presents survey evidence on the role that angel investors play in funding small, nascent firms. As we later show, the deals we examine here share many similarities with venture capital deals. However, the alliance contracts in our paper differ from VC contracts in one critical respect: VCs provide funding for firms while clients in alliance transactions provide funding for projects inside firms. The incentive problems created by the separation of ownership and control have long been a central concern of corporate finance, and understanding how these is manifested in the contract is an important part of our analysis. In this regard, our work builds on and extends the earlier analysis of Lerner and Merges (1999), which examines how the allocation of broadly defined control rights to the R&D firm varies with the availability of outside funding, or Allen and Phillips (2000), which examines post-announcement operating performance in a sample of equity-backed alliance agreements.

Several important pieces of analysis are currently missing from the paper as it now stands. First, without more details of the pre-existing financial relationships that these research firms have with other pharmaceuticals and with other financial partners (such as venture capital funds), we are omitting a potentially vital dimension along which contracts may differ. It could well be

the case that contracting parties piggyback on monitoring mechanisms that have been put in place through pre-existing agreements, and that this behavior accounts for the variation we see in the equity stakes that are present. Data on pre-existing deals and prior VC activity will speak to this question. In addition, analyzing follow-on deals written between the firms in our sample would not only increase our sample size, which would improve the power of our empirical tests, but would also shed further light on this issue. Finally, incorporating information from market reactions, and information about the success of projects would help us to understand the contractual determinants of success—if any—in strategic alliances. We intend to address these issues in future drafts.

The remainder of the paper is organized as follows. We begin by outlining the theoretical background. This is contained in Section 2. In Section 3, we describe the data set we have compiled, while in Section 4 we present the details from our 75 contracts. Section 5 presents results from regressions that relate contract characteristics to firm and dyad characteristics. Section 7 concludes by offering future theoretical and empirical research directions suggested by our findings.

2 Theoretical Motivation

A common element in the deals we analyze is the nature of information and the timing of actions between the research organization and the pharmaceutical company. All of the deals we analyze concern early stage (i.e. pre-clinical) research. As such, the research company often has specialized knowledge that the pharmaceutical lacks pertaining to the use of a particular technology. In the case of genomics-based research, their specialty lies in identifying gene-based disease triggers that the pharmaceutical later screens against a database of compounds. The pharmaceutical plays a dual role as investor—either through

licensing and royalties, through equity, or both—and consumer of the research output, since it takes the R&D firm’s output and uses in the further development of a drug. In terms of the nature of the contracting problem faced by the two parties, a time line common to these projects is as follows:

Time 0: Would-be alliance partners meet, conduct due diligence, and bargain over a potential collaboration. If successful, a contract is written at this time.

Time 1: The R&D firm expends effort identifying drug targets. If a target is found, it is passed to the client for further development at time 2.

Time 2: A suitably identified target is transferred to the client firm, which then integrates this into the discovery and production of some final drug product.

Time 3: Revenues from the final product occur and are disbursed according to the agreement.

This paper is of course concerned with the specific nature of the details in the contract written at time 0, how these details reflect anticipated behavior at time 1 and 2, and what scope exists for altering or cancelling the contract after time 0. These considerations are in turn a function of the structure of information and the nature of the anticipated incentive conflict between the firms at time 0.

The nature of the activity described above approximates a number of theoretical models of incomplete contracts. In particular, the role of the client in this relationship is a hybrid between the consumer/financier in the Aghion and Tirole (1994) model and that of the VC in models by Casamatta (2000), Repullo and Suarez (1999), Cornelli and Yosha (1997).

Aghion and Tirole (1994) model an incomplete contracting situation between a customer/end user of R&D, and a penniless entrepreneur/researcher who engages in unverifiable effort to generate an R&D output. In their model, both agents supply an input (the customer’s input can be thought of as financial

investment) that jointly affects the probability of R&D success, and bargain over a transfer price in the event that the efforts result in success. Their results echo the standard prescriptions from Grossman and Hart (1986) and Hart and Moore (1990), namely that when contracts are incomplete, ownership should be tilted towards the agent whose marginal impact on the value of the project is highest. This is perhaps the most compelling explanation for why these contracts occur between two firms, and not within a firm, where ultimate ownership would not rest with the researcher.¹ In addition, their theory also provides for ‘shop rights,’ which in our context coincide with the R&D firm’s right to own (for the purposes of later development) rights to certain compounds that are not selected by the client.

But a number of features of the Aghion and Tirole (1994) model seem at odds with the data we present here. Most importantly, in their model equity ownership is irrelevant, since it has no effect on the real transfer price of the R&D output: any combination of equity and a license fee can be mimicked by a lower equity stake and a license fee adjusted upward to reflect the difference in the license fee not internalized through ownership. As they explicitly point out, however, a host of questions concerning ownership and management of research processes and mitigating problems with spillovers may give rise to the need for equity.

Motives for equity participation arise in Repullo and Suarez (1999) and Casamatta (2000), where a double-sided moral hazard problem that arises from the financiers dual role as investor and adviser makes the use of equity desirable. Casamatta (2000) shows that in general, when the financier also provides a complementary input (advisory services in her model) equity is necessary to provide the financier with appropriate incentives. Her model develops a predic-

¹ Aghion and Bolton (1992) provides another motive for why these activities occur in alliances as opposed to within the firm—namely, when the private benefits to the R&D are co-monotonic with the social value of the project (the sum of private and monetary benefits to both parties), ownership by the R&D is optimal.

tion that common equity should occur when the financier’s investment is low, but convertible preferred equity should occur when the financier’s investment is high.

An alternative explanation for convertible securities is provided by Cornelli and Yosha (1997). In their model, the financier’s conversion dilutes the entrepreneur’s claim; this provides an incentive for the manager not to ‘window-dress.’ In our context, this explanation coincides with the use of convertible securities as a mechanism to prevent the R&D from extending the project past the point at which the client would like it to terminate by reporting promising, but unverifiable progress.

Finally, a number of models highlight the importance of liquidation rights, contingent allocation of control, and renegotiation. [To be completed.]

3 Data

The data we use for this study come from a database (www.rdna.com) assembled by Recombinant Capital, a biotechnology industry analysis firm that provides access to a wide range of contract-related information based on data culled from public filings, news releases, and presentations at industry conferences. Recombinant Capital not only tracks inter-firm collaborations in human medicine, but also agreements involving universities, and collaborations in related fields such as agricultural technology and veterinary medicine. In order to remove one potential source of contractual variation, we focus exclusively on genomics deals initiated between a drug and a biotech, or between two biotech firms prior to 1998. Broadly speaking, genomics involves using advances in biology and genetics to understand disease processes at the cellular level. Functional genomics specifically entails locating genes that contribute to disease in affected cells.

Genomics companies work at the first stage of the contemporary drug development process: they identify “drug targets”—enzymes or receptors that trigger or block biochemical processes within a cell. The biological role of these targets in disease initiation or progression is then “validated,” a process which entails proving that a DNA, RNA, or protein molecule directly participates in a disease process and is therefore a suitable target for development of a new therapeutic compound. Validated targets are then “screened” against (typically hundreds of thousands) molecules, with the aim of pinpointing compounds that trigger or block the processes precipitated by the focal targets. In all of the alliances we examine in detail, the biotech partner identifies and validates targets, which are then developed in collaboration with the client. In some of the partnerships, the biotech partner will also screen compounds against targets, and thus transfer lead development compounds to the client. Although biotech firms continue to expand downstream in the drug development chain, the client in the partnership typically conducts the subsequent steps in the drug development process, including animal testing, clinical trials, large-scale manufacturing, and sales and marketing. Roughly speaking, one can think of these alliances as vertical transactions in which there is an upstream / downstream division of effort between the biotech firm and the client in the deal.

The sample was created by searching the `rdna.com` database on the keywords “Combinatorial,” “Gene Expression,” “Gene Sequencing,” “Pharmacogenomics,” “Proteomics,” “Screening,” and “Transcription Factors.” In addition, we restricted attention to deals that were already ‘analyzed’ by Recombinant Capital, which means that Recombinant Capital employees had synthesized the SEC filings and news announcements into a common document format. Using these screens yielded 218 deals, some of which seem inappropriate for the present analysis, given that they are primarily licensing agreements for already-existing products (for instance, granting access to a

proprietary database). For these deals, it is not clear what the intra-firm alternative to the alliance is, and what organizational implications the alliance may have on either counterparty. Since our objective is to understand complex inter-firm relationships, not genomics *per se*, we exclude 66 such deals based on subjective evaluation, leaving a total of 152 deals. This process is described in Table ??.

From this restricted sample, we draw 75 contracts in such a way as to maximize the number of firms (biotechs and pharmaceuticals) that are represented in the final sample. Given that 75 contracts are used, a maximum possible 150 firms could be present if no firms appeared more than once. As Table ?? shows, our final sample contains a total of 107 distinct firms, of which 51 are biotech firms and 56 are pharmaceutical firms. One firm, Sugan, appears both as a biotech and a client; not only has it written deals with larger pharmaceuticals, but it also has sponsored research at other biotech firms.² Of the 51 biotech firms represented, one-third were publicly traded at the time the deal was announced, while 18 of the remaining 50 (36%) later went public.

One shortcoming to our approach is that it is ultimately based on publicly available information, and thus many confidential terms are hidden from us. At the same time, we can conduct tests based on market reactions and subsequent performance that are not normally available in detailed studies of other types of contracts. This allows us to build on previous results that highlight the role of equity as a mechanism for allocating control (Pisano, 1989; Robinson and Stuart, 2000; Boone, 2001). Whereas many papers simply assume that equity stakes confer control rights, citing the incidence of board seats granted in conjunction with larger equity stakes, our analysis provides details which

² This is common in the biotechnology sector; Robinson and Stuart (2000) report that 1011 of 3854 deals are between two biotech firms. In our overall sample of 218 firms, 39 deals are ones between two biotechs, involving a total of 27 biotech research sponsors. Fifteen biotechs appear as both client and research firm in our sample of 218 firms.

sharpen this intuition. The propensity of equity deals to involve detailed prohibitions on amassing shares in the open market subsequent to the alliance suggests that equity confers control even when it is not accompanied by board seats, voting rights, or other similar measures.

Of the 75 contracts in our sample, 72 are strategic alliance agreements and the remaining 3 are joint ventures. A total of 44 of the 72 strategic alliance agreements involved equity participation, while 2 of the 3 joint ventures involved equity participation. (The joint venture without equity participation was the Monsanto Millennium agricultural genomics joint venture, a large deal involving a \$38 million up-front cash payment from Monsanto to Millennium.) A total of 66 deals explicitly deal with licensing issues, but only one of these was a joint venture.

In part, our sampling strategy reflects the limitations associated with working with data derived from publicly available sources. Due to SEC disclosure provisions, many dollar amounts and percentages are omitted from our documents.³ On the other hand, since many of the firms in our sample are publicly traded, we have access to information (financials, stock price reactions) that is often lacking in the study of venture activity.

Table 2 shows the sample characteristics over time. While alliances appear every year from 1990 to 1998, the spike in activity in the 1995-1997 period means that over half occur in this three-year interval. While only two alliances were recorded in 1990, both involved equity, and the average of these equity stakes is roughly twice that of the next highest year's average. Upfront payments, on the other hand, are clustered towards the end of the sample, as are deals between two R&D firms. The number of deals involving publicly traded also trends upward through the sample, perhaps reflecting the number of prior

³ Lerner and Merges (1999) overcome this problem by simply measuring the number of different types of control mechanisms allocated to the biotech firm.

IPOs in biotechnology. At the same time, the mean size of the deal (a number which includes upfront payments as well as contingent payments that may not occur, but nevertheless approximates the total potential commercial value to the R&D of the project) trends upward too. If we were to extend this sample forward past 1998, we would see genomics-related alliance activity explode. This coincides in part with the push to map the human genome.

4 A Closer Look at Contract Characteristics

In this section, we examine the features of these contracts by focusing not only on specific examples that illuminate the difficulties inherent in the alliance, but also by presenting tabulations of key contract characteristics.

4.1 *R&D Staging*

Every contract in our sample involves the use of staged financing that coincides with research milestones. The BMS/Cadus deal specified a three-year research period with an option to extend, while the other two specified five-year research periods. The BMS/Cadus deal also specified that up to \$4 million per year in research funding would be provided for Cadus, and according to its 1996 annual report, it had received \$10.4 million in funding from BMS during the first two years of the agreement.

For 68 deals it is possible to determine the expected length of the collaboration based on the initial contract. This is presented in Table 4. The mean and median are both approximately four years, but the maximum length is ten years, and this occurs in three deals. This length reflects the expected time that both parties anticipate the alliance will last at the inception of the project, as reflected by the contract. Of the remaining 7 deals, only the deal between

Ortho Biotech and Cell Therapeutics did not specify an alliance length. The other 6 were either confidential or not available.

Another important part of the terms of R&D is the provision for labor allocation. The Biogen/Curagen and Millennium/Bayer deals both specify a certain number of full-time equivalents (FTEs) to be devoted to the project, while the BMS/Cadus deal does not. Generally, the number of FTEs is confidential in our data, however its very presence is interesting given the potential difficulty in verifying that labor is actually being supplied. That these contracts include what might be regarded as unverifiable actions suggests that theories of implicit contracts along the lines of Baker, Gibbons, and Murphy (1998) may help describe why alliances are successful.

Indeed, Table 4 indicates that of the 75 deals included in our analysis, 33 specify the number of full-time equivalents (FTEs) devoted to the research project. Is this labor input verifiable? Perhaps not, but eleven alliance contracts go further and state that a specific grade or education level be used—for example, this might state that the personnel be appropriately qualified in biochemistry or biology, or that they hold Ph.D.s. A further 9 specify that certain, named personnel be employed strictly on a particular project, that they not be allowed to work on other projects, and that if they should no longer be employed, that the deal should be renegotiated. On the one hand, this indicates that the contracting parties seem aware of the inalienability of the human capital involved in the research process, but on the other hand it is hard to say whether, based on arguments such as Hart and Moore (1994), we should expect more or less than 9 contracts to have such provisions.

The source of incentive conflict in many financing theories is private benefits; in models of internal capital markets such as Stein (1997), Stein (2000), and others, managers are motivated by non-appropriable private benefits. One potential source of private benefits in the deals we analyze are publications

arising from discoveries. These scientific publications seem like an important of compensation for scientists and are inherently tied to project outcomes. In fact, many scientists at biotech firms are prolific contributors to the scientific literature. Evidence from Stern (1999) indicates that these scientists forgo substantial wage income for the ability to publish in scientific journals. Interestingly, the terms of the R&D section of the contracts provide guidelines for publishing academic articles based on scientific discoveries related to the alliance. While many deals place strict prohibitions on this activity, others permit it given appropriate permissions have been obtained. In the Millennium/Bayer deal, notice must be

“given 60 days prior to submission to other party. If the other Party informs such Party that its proposed publication could be expected to have a material adverse effect on any Patent Rights or Know-How of such other Party, then such Party shall delay such proposed publication sufficiently long to permit the timely preparation and first filing of patent application(s) on the information involved. Millennium shall not permit a publication that includes information relating to a Bayer Development Candidate without the prior approval of Bayer.”

The BMS/Cadus and Biogen/Curagen deals simply specify written prior consent.

4.2 Collaboration Management

Collaboration management is an area in which surprisingly little variation across contracts exists. Equal representation on management committees is the norm, and majority or unanimity is almost always required in order to act on a decision.

The Millennium/Bayer, Curagen/Biogen, and BMS/Cadus deals contain very

similar provisions for collaboration management. In all three cases, the deal specifies equal representation from the client and R&D on the project-level committees. In the BMS/Cadus deal, Cadus was responsible for appointing the project coordinator, while the others simply state equal numbers at each level of decision-making. Decisions in the Millennium/Bayer deal are made on the basis of majority opinion, whereas the other two deals require unanimous opinion, and the Millennium/Bayer deal specifies project-level committees as well as a joint steering committee. The distinction, then, is whether a single member of an opposing firm can block a decision, or whether all members of the opposing firm must act in concert to block a decision of the committee.

A far greater degree of oversight appears in these deals relative to what one would expect in venture capital agreements. Moreover, this oversight is not part of an initial control stake maintained by the VC which fades as the project matures; if anything, given the vertical nature of the relationship between the R&D firm and the client, the value of control may in fact increase as the project matures.

4.3 Equity and other Financing

A key element to the deals we analyze is equity cross-ownership. As Allen and Phillips (2000) show, equity ownership in strategic alliances is common across a wide range of business activities. The deals we describe fit the pattern laid out in Allen and Phillips (2000), in which the larger firm takes an equity position in the smaller firm as part of the funding of the collaboration it sponsors. In this section, we focus not only on the presence of equity, but also with the contractual arrangements that surround the equity stake.

The Millennium/Bayer deal included just over \$96M in equity for Millennium Pharmaceuticals. With this came the right for a Bayer representative to at-

tend Millennium board meetings semi-annually. The terms of their agreement specified that Bayer would pay 115% of the maximum of (i) the average Millennium stock price between March 1, 1998 and August 31, 1998, and (ii) the stock price on 21 September, 1998. In fact, the historical average was higher.

The deal was signed on 22 September, 1998. Millennium's stock price dynamics around that date were as follows: on Friday, 18 September, it traded at \$14.31/share. The Monday, 21 September, price jumped to \$16.50, and the price on the 22nd continued upward to \$17.25. This high price continued throughout the year.

One of the interesting features of this transaction was the manner in which contingencies were written into the equity agreement. Since privately negotiated equity placements such as these cannot generally be liquidated through public sale for two years and without prior registration, the assignment of demand and piggyback registration rights is potentially important.⁴ The contract provided Bayer with two demand registrations and unlimited piggyback registrations. In addition to these rights, Bayer was prohibited from transferring or selling more than 2.5 million shares in any one year—this prohibition was erased if Millennium entered into a merger agreement. Bayer was entitled to maintain its pro rata share ownership in Millennium, but only if Bayer had not sold more than one million shares over the life of the agreement. Not only was Bayer restricted in its ability to sell Millennium stock; Bayer was also prohibited from increasing its share ownership in Millennium for three years after the signing of the contract.

BMS provided Cadus with \$20 million in three separate equity transactions. The first two transactions involved \$12.5 million (in July, 1994) and \$5 million (in September, 1995) of Class B convertible preferred stock, purchased at a

⁴ Demand rights allow the holder to force the other firm to register its stock for sale; piggyback rights allow the holder to include its shares in any registration initiated by the other firm.

share price of \$3.50 and \$4, respectively. The second equity purchase occurred as a result of Cadus achieving a research milestone. Finally, at the IPO of Cadus in July, 1996, BMS converted its B shares into 1.607 million common shares, and purchased an additional \$2.5 million worth of common shares at \$7/share.

The Biogen/Curagen deal is unusual in that it combines equity and debt. Biogen purchased \$5 million of common equity in Curagen at its IPO price of \$11.50/share. The terms of the purchase were such that if Curagen did not IPO within 18 months of the deal date, Biogen had no obligation to purchase further stock—effectively it acted as a large shareholder in the IPO. It also provided a \$10 million loan facility. The loan was repayable in cash or Curagen common stock (at current market prices) at the sole discretion of Curagen.

More evidence on the role of equity can be found in Table 3.

4.4 Licensing Terms

A key feature in almost all biotech strategic alliances is the licensing agreement that supports the exchange of revenues between the companies once a drug candidate has been identified. In terms of the time line at the beginning of this section, the licensing agreement takes effect at time 2, once the R&D output has been transferred upstream, and specifies the behavior of the client at time 3. One of the interesting features of strategic alliances in biotechnology, as suggested by Table ?? and as also shown in Robinson and Stuart (2000), is that the licensing agreement is written at the inception of the contract, before the object of the license exists. The alternative to this, which would perhaps be more natural from the point of view of contract theory, would be to postpone the licensing agreement until a discovery materialized. It seems noteworthy that contracts typically do not state that the parties agree to

determine licensing terms at a later date.

Each of the three deals described here provides an exclusive license to the client for any compounds that are identified as suitable candidates. (Identifying candidates for the client, after all, is the primary objective of the alliance.) In the Millennium/Bayer deal, Bayer received an exclusive license with respect to selected targets, but only a non-exclusive license with respect to targets that were returned from the selection process. Unfortunately, the royalty rates associated with these licenses are confidential, but we do observe variation in the manner that revenues are divided between the firms: the Millennium/Bayer and BMS/Cadus deals confer worldwide licensing rights to clients for all disease categories, while the Biogen/Curagen licensing revenues are split according to disease category.

Table 4 provides evidence on how licensing arrangements are affected after a deal is terminated. It shows that in 46 of the 75 deals in our sample, ownership reverts back to the R&D after a project has been terminated, provided that the contract did not end due to R&D breach. A further 9 deals provide for the non-breaching party (without explicitly naming the R&D) as the one who receives post-termination rights, while only 5 involve the use of a sharing rule. That such a small fraction involve co-ownership supports Aghion and Bolton (1992), who show that typically co-ownership is sub-optimal relative to contingent ownership, since the former exacerbates holdup problems.

4.5 Termination Rights

Termination rights are a central part of the theories of Bolton and Scharfstein (1990) and Hart and Moore (1998), in which the outside financier's ability to shut down the entrepreneur's project at some intermediate stage (before unobservable cash flows arrive) provides the entrepreneur with incentives not

to enjoy too many private benefits.

There are essentially two aspects of termination provisions. One concerns who is allowed to terminate the deal, and under what circumstances. The second concerns what happens to the existing intellectual property after the termination.

Regarding the first point, the three alliances we scrutinize differ in how they allocate termination rights. The BMS/Cadus deal allocates termination rights to both the client and the R&D equally—each may terminate by material breach only. In the Biogen/Curagen deal, Curagen’s right to terminate is limited to uncured material breach, but Biogen has substantially more rights. Biogen too has the right to terminate for uncured material breach or bankruptcy, but also may terminate any time after the second anniversary with six months’ written notice. In this event, the contract states that any such early termination shall not affect any license agreement.

The deals also differ in terms of what happens to existing alliance resources after the termination. The Biogen/Curagen deal effectively states that all resources that are not part of an ongoing license shall be returned to the original creator of the resource—all client proprietary material shall be returned to the client or destroyed, likewise with all R&D material. The other two deals make no such provision, except to state that existing licenses outlive any termination. Finally, the three deals coincide in their treatment of transferring technology: each deal prohibits one firm from transferring technology to a third party without written consent of the counterparty, except in the event of a sale or merger.

These findings suggest that termination rights do more than simply provide incentives. Termination rights seem to play an important role in the manner in which intellectual property and other resources are appropriated at the project level, and kept from being implemented in other projects that one firm have

in operation.

Table 4 provides further evidence on how alliances end.

5 Regression Results

To be completed. See tables 5, ??, 3 and ??.

6 What Is Missing From These Contracts?

Up to this point, we have focused on what is present in strategic alliance contracts: how financing terms and collaboration management are used together to manage investment projects that are carried out in separate firms. In this section, we ask what might be present in these contracts but instead is missing. In order to do that, we compare alliance contracts with other types of financial contracts that have received recent empirical attention.

6.1 *Strategic Alliances and VC Funding*

Because these contracts often represent the most important means of financing for small biotechnology firms, venture capital contracts provide a natural point of comparison. Alliance agreements look similar to venture capital agreements in a number of respects: they involve staged capital infusions based on performance milestones that mirror the financing rounds in VC deals; they frequently involve the use of equity, and in particular, convertible preferred stock; and monitoring occurs frequently through board representation. Like Kaplan and Strömberg (2000), we find that these contracts separately allocate control rights, cash-flow rights, liquidation rights, and board rights. In

addition, our contracts frequently discuss patent rights and publication rights, which in our context can be interpreted as private benefits or non-monetary compensation.

Yet these contracts differ from venture capital deals in important ways. The fundamental distinction is that VCs fund the development of *firms*, whereas alliance agreements fund the development of projects *inside* firms. This means that in alliance agreements, significant resources go into delineating the acceptable use of resources in non-project related activities in a way that is not present in VC deals. Prototypical deals between VCs and entrepreneurs typically involve the VC maintaining cash flow rights but ceding control as the entrepreneur's business matures. Not so with alliance contracts. Due to the vertical nature of the relationship between the R&D firm and the pharmaceutical organization, trading off control and residual income over the life of the project is less common. For example, collaboration management is typically handled by a project team comprising members in equal numbers from both the biotech and the pharmaceutical. Decision making is often by unanimous vote, but given the ubiquity of equal representation, even majority voting allow either party to block decisions they view as inappropriate. This differs from what we see in venture capital, where VCs frequently sit on boards (Lerner, 1995) and have voting rights (Sahlman, 1990; Kaplan and Strömberg, 2000), but do not have day-to-day, operational decision-making rights.

7 Conclusion

This paper examines the details of 72 strategic alliance agreements and 3 joint ventures. In each of the 75 cases, the collaboration centers on using one firm's expertise in genomics to identify and discover drug candidates that will later become part of the other firm's product pipeline.

Because these deals provide a major source of funding to small, nascent (often pre-IPO) firms, part of our analysis compares these contracts with venture capital deals. Like venture capital deals, the projects often involve staged capital infusions triggered by successful completion of milestones, the use of convertible, preferred equity and debt, and the allocation of monitoring rights through board membership.

But the comparison with venture capital does not fully explain the complexities of the inter-firm collaborative agreements we study. An important component of the contract is delineating the boundaries of the project of interest, and keeping its resources and revenues separate from the rest of the firm responsible for its execution. Thus, we commonly see project-level operational decisions made in teams of equal numbers from both firms. Contracts also clearly specify rights pertaining to the use of intellectual property that arises.

This suggests that an important direction for theoretical progress on alliances and ventures lies in understanding the mechanisms behind verifying resource allocation between projects at the research firm. Gaining a better understanding of inter-firm collaboration is likely to increase our understanding of internal capital markets and decision-making inside firms, as well as shed light on the issues relating to the determinants of the boundaries of the firm.

References

- AGHION, P., AND P. BOLTON (1992): “An incomplete contracts approach to financial contracting,” *The Review of Economic Studies*, 59(3).
- AGHION, P., AND J. TIROLE (1994): “The Management of Innovation,” *Quarterly Journal of Economics*, 109(4), 1185–1209.
- ALLEN, J. W., AND G. M. PHILLIPS (2000): “Corporate Equity Ownership, Strategic Alliances, and Product Market Relationships,” *Journal of Finance*, 55(2).
- BAKER, G., R. GIBBONS, AND K. J. MURPHY (1998): “Implicit Contracts and the Theory of the Firm,” NBER Working Paper.
- BOLTON, P., AND D. SCHARFSTEIN (1990): “A Theory of Predation Based on Agency Problems in Financial Contracting,” *American Economic Review*, 80(1), 94–106.
- BOONE, A. (2001): “The Interaction of Ownership, Governance, and Product Markets: Evidence from Equity Carveouts,” Working Paper, Penn State University.
- CASAMATTA, C. (2000): “Financing and Advising: Optimal Financial Contracts with Venture Capitalists,” CEPR Discussion Paper.
- CORNELLI, F., AND O. YOSHA (1997): “Stage Financing and the Role of Convertible Debt,” CEPR Discussion Paper 1735.
- GROSSMAN, S., AND O. HART (1986): “The costs and benefits of ownership: a theory of vertical and lateral integration,” *Journal of Political Economy*, 94(4), 691–719.
- HART, O., AND J. MOORE (1990): “Property Rights and the Nature of the Firm,” *Journal of Political Economy*, 98.
- (1994): “A Theory of Debt Based on the Inalienability of Human Capital,” *Quarterly Journal of Economics*, 109(4), 841–879.
- (1998): “Default and Renegotiation: A Dynamic Model of Debt,” *Quarterly Journal of Economics*, 113(1), 1–41.
- HELLMANN, T. (1997): “A Theory of Corporate Venture Investing,” Working Paper No. 1452, Stanford University.
- KAPLAN, S. N., AND P. STRÖMBERG (2000): “Contracting Theory Meets Reality: An Empirical Investigation of Venture Capital Contracts,” Working paper, University of Chicago.
- LERNER, J. (1995): “Venture Capitalists and the Oversight of Private Firms,” *Journal of Finance*, 50(1), 301–318.
- LERNER, J., AND R. P. MERGES (1999): “The control of strategic alliances: an empirical analysis of biotechnology collaborations,” Working paper, NBER.
- NATIONAL SCIENCE BOARD (2000): “Science and Engineering Indicators – 2000,” Discussion Paper NSB-00-1, National Science Foundation, Arlington, VA.
- PISANO, G. (1989): “Using equity participation to support exchange: evidence from the biotechnology industry,” *Journal of Law, Economics, and*

- Organization*, 5(1).
- REPULLO, R., AND J. SUAREZ (1999): “Venture Capital Finance: A Security Design Approach,” Working Paper, CEMFI.
- ROBINSON, D. T., AND T. E. STUART (2000): “Just How Incomplete Are Incomplete Markets? Evidence from Biotech Strategic Alliances,” Working Paper, University of Chicago.
- SAHLMAN, W. A. (1990): “The Structure and Governance of Venture-Capital Organizations,” *Journal of Financial Economics*, 27, 473–521.
- STEIN, J. C. (1997): “Internal Capital Markets and the Competition for Corporate Resources,” *Journal of Finance*, 52(1), 111–133.
- (2000): “Information Production and Capital Allocation: Decentralized vs. Hierarchical Firms,” Working Paper.
- STERN, S. (1999): “Do Scientists Pay to be Scientists?,” NBER Working Paper w7410.
- WONG, A. (2001): “Angel Investors,” Dissertation, University of Chicago, Chicago, IL 60637.

Table 1
Contract Characteristics over Time

This table describes the time-series of alliance announcements in our sample, along with other key sample characteristics. Total deals is the number of announcements in year t , while mean size is the mean of total pledged funding as recorded by Recombinant Capital (this includes contingent funding). Expected Length is the number of years that the collaboration is expected to last. Equity deal is the number in which the client purchased equity in the target, along with the mean equity stake, in millions of dollars. The ‘Up-Front Fee?’ columns record the number each year that involved upfront cash payments.

Year	Total		Mean	Expected	Equity		Upfront	FTEs	Pay Grade		Persons		Screening		Lead
	Deals	Size			Length	Deal			Stake	Fee?	Specified	Named	Named	Deal	
1990	1	29.50	5.00	1	5.00	0	0	0	0	1	1	0	0	0	0
1991	8	16.88	3.25	4	3.00	3	1	1	0	0	0	4	4	0	0
1992	11	14.17	4.23	7	3.18	4	4	4	3	2	2	7	7	1	1
1993	9	29.21	3.19	6	3.34	4	4	4	1	1	1	6	6	1	1
1994	14	48.85	3.64	11	7.26	1	7	7	1	1	1	7	7	0	0
1995	27	45.45	3.63	18	4.87	7	13	13	3	5	5	12	12	2	2
1996	15	41.61	3.58	10	3.70	6	9	9	1	1	1	7	7	3	3
1997	29	54.49	3.98	19	6.33	8	12	12	2	5	5	14	14	1	1
1998	12	60.53	4.11	5	1.58	2	7	7	1	0	0	7	7	3	3
Overall	126	37.85	3.85	81	4.25	35	57	57	12	16	16	64	64	11	11

Table 2
Characteristics of Sample R&D Firms over Time

This table describes the characteristics of R&D firms in our sample. Total Firms is the number of distinct firms in our sample in a given year. Firm Value is the value of the R&D firm, as recorded by Recombinant Capital. This figure is based on the last recorded valuation for private firms, and is otherwise the market value of equity. 'Then Public' records the number of R&D firms that were publicly traded at the time of the announcement, while 'Later Public' records the number of non-publicly traded firms that later went public after the time of the alliance. 'Percent venture' records the (mean) fraction of R&D firm's shares outstanding owned by VC interests. Prior deals measures all corporate transactions recorded by the Recombinant Capital funding database—this includes private equity investments, venture funding, and other sources of funding, but excludes IPOs and option or warrant exercises. Prior alliances measures previous alliance activity in three ways. 'Last 5 Years' measures total alliance activity (with both other biotechnology firms as well as pharmaceuticals), 'Overall' measures all recorded alliance activity for the firm, while 'Equity' activity measures all prior equity alliance activity.

	Total Firms		Firm Value		Firm Age		Then Public	Later Public?	Percent VC	Prior Deals	Prior Alliances:		
											Last 5 Yrs.	Overall	Equity
1990	1	10.4	2.58	0	1	14%	6.00	1.0	0.0	0.0	0.0	0.0	0.0
1991	7	78.7	1.61	2	4	57%	4.14	3.0	2.6	1.1	3.0	2.6	1.1
1992	10	130.6	3.19	2	2	43%	5.30	3.8	4.9	2.5	3.8	4.9	2.5
1993	8	78.2	3.27	2	5	59%	7.11	3.9	4.4	1.1	3.9	4.4	1.1
1994	12	84.6	3.94	5	7	49%	7.09	4.8	7.4	2.8	4.8	7.4	2.8
1995	19	95.4	4.63	7	12	54%	7.91	4.7	6.7	2.4	4.7	6.7	2.4
1996	12	101.8	4.91	6	7	50%	7.50	5.8	7.7	1.7	5.8	7.7	1.7
1997	23	171.9	4.67	15	8	41%	8.70	7.3	11.0	3.2	7.3	11.0	3.2
1998	10	290.2	5.54	7	5	32%	10.50	0.0	0.0	0.0	0.0	0.0	0.0
	102	115.8	3.82	46	51	44%	7.14	3.8	5.0	1.6	3.8	5.0	1.6

Table 3
The Use of Equity in Alliance Agreements

This table summarizes equity participation in biotech strategic alliances for our sample of 126 firms. Panel A contains data for all 127 firms; Panel B only summarizes information for firms that were not publicly traded at the time of the alliance, while Panel C summarizes information for the complement. Total deals is the number of deals containing equity, common equity, or preferred equity. Convertible denotes the subset of preferred equity transactions that could be identified as convertible equity. Mean and median amount are in millions and refer to the size of the equity stake. Mean Fraction expresses the equity stake as a fraction of the total R&D firm value, which is based on the firm's valuation in its last venture round. Board seats is the number of equity deals in which a board seat is granted to the client firm as part of the deal (in all but one case, a single seat is given). IPO tie-in refers to whether the initial equity stake is part of a planned IPO of the R&D firm. This includes situations in which the alliance coincides with the R&D's IPO, and when the alliance calls for the client to increase its equity stake at the time of the IPO. Loan tie-in refers to deals in which the equity stake is tied to the repayment of a loan provided to the R&D by the client.

	Total Deals	Mean Amount	Median Amount	Mean Fraction	Board Seats	IPO Tie-Ins	Loan Tie-Ins
Panel A: All Firms, N=126							
Total	82	7.39	5.4	11	11	15	11
Common	40	8	5	6.5	5	6	8
Preferred	42	6.85	6	14.95	6	9	3
Convertible	32	7.22	6.25	14.6	4		
Panel B: Pre-IPO Firms, N=72							
Total	54	5.93	5	12.05	9	15	7
Common	14	4.35	4	7.8	3	6	5
Preferred	40	6.45	6	13.7	6	9	2
Convertible	30	6.7	6.2	13.06	4		
Panel C: Post-IPO Firms, N=55							
Total	28	10.43	8.25	9	2		4
Common	26	10.43	8.25	6.4	2		3
Preferred	2	14.5	14.5	32.3	0		1
Convertible	2	14.5	14.5	32.3	0		

Table 4

How Alliances End: Termination Provisions and Ownership Reversion

This table describes termination provisions and ownership reversion upon termination for a sample of 126 strategic alliance contracts. Ownership reverts to R&D includes all situations in which ownership reverts to the R&D, including cases in which ownership reverts with exceptions. (54 of 75 contracts stipulate that ownership reverts to R&D with no further language.)

Termination Provision	Both/ Either	Only R&D	Only Client	Examples
Uncured Breach Only	0	4	0	Either party may terminate by breach, by bankruptcy, by mutual agreement, or if the other party is acquired by any third party
Uncured Breach	100	0	0	
If Change in Control	11	0	38	
At Will	4	0	16	... may be terminated by [Client] any time after the 3rd anniversary of signing; ...
At Will after Certain Date	8	0	51	
If Insufficient Progress	9	1	20	may be terminated by [R&D] if [Client] has not selected a [Target] for further evaluation prior to the expiration of the Research Period
If Change in Key Employees	0	0	8	In addition, [Client] shall be entitled to terminate the Program upon 90 days' notice after the date that any of [person], [person] or [person] is no longer obligated or able to continue to provide the same level of services as contemplated at the signing of this Agreement.
Reversion Provision	Both/ Orig.	R&D	Client	
Reverts to Non-Breaching	12	0	0	
Reverts to Non-Terminating	6	0	0	
Failures Revert to	0	2	0	
Ownership Reverts to	14	75	6	
Except for: Breach		18	0	
Change in Control		3	0	
Bankruptcy		12	0	

Table 5

Correlations in Contract Characteristics

This table presents pairwise correlations between contracting variables. Correlations denoted with stars are significant at the 10% level. (Diagonal elements are omitted.) Project stage is a variable that equals 1 if the project is discovery stage (107 deals), 2 if it is lead molecule stage (11), 3 if pre-clinical (7), or 4 if phase I FDA trials (2 deals). Project Term is the expected length of the alliance as stated in the contract at signing. Project size is the total amount of financial outlays (both actual and contingent) that the client pledges to the R&D. Equity 0/1 is an equity dummy, while Equity stake measures the size of the equity purchase in millions. Equity fraction measures the equity value as a fraction of the value of the R&D firm as of the last time it received funding. Upfront and Royalty measure payments from the client to the R&D. Employment variables record whether the contract stipulates a certain number of full-time equivalents (FTEs), stipulates their level of training (PhDs), or names specific individuals as project members (Names). R&D Puts refers to whether the equity contract allows the R&D to put additional shares to the client; Warrants refers to whether the client has the right to increase its equity stake. These are only defined for equity deals.

	Project			Equity		R&D Age	VC Frac.	Firm Value	R&D Puts	War-rants	Roy-alty?	Up-front?	Employment	
	Stage	Term	Size	0/1	Stake								FTEs	PhDs
Proj. Term	-0.16*													
Size	0.08	0.55*												
Equity: 0/1	-0.13	0.25*	0.23*											
Stake	-0.04	0.50*	0.48*	0.56*										
Frac.	-0.14	0.40*	0.22*	0.53*	0.48*									
R&D Age	0.17*	0.02	0.08	-0.21*	0.03	-0.14								
VC Frac.	-0.06	-0.12	-0.20*	-0.07	-0.17	-0.01	-0.54*							
Firm Value	0.15	0.29*	0.41*	-0.01	0.34*	-0.24*	0.18*	-0.36*						
R&D Puts	-0.12	0.40*	0.36*	.	0.31*	0.23*	0.06	-0.05	0.06					
Warrants	-0.11	0.29*	0.17	.	0.26*	-0.05	-0.05	-0.10	0.50*	0.17				
Royalty?	0.47*	0.09	0.21	-0.13	0.32	0.17	0.49*	-0.25	0.41*	0.42	0.21			
Upfront?	0.37*	-0.19*	0.25*	-0.14	0.07	-0.12	0.02	-0.07	0.29*	-0.09	-0.03	-0.13		
FTE?	-0.07	-0.04	-0.01	0.07	0.01	-0.03	0.08	0.05	-0.14	-0.02	0.06	0.02	-0.03	
PhDs	0.09	0.01	0.02	0.07	0.01	0.07	-0.08	0.10	-0.16	-0.12	0.03	-0.24	-0.02	0.09
Names	0.00	0.14	0.15	0.13	0.19*	0.23*	-0.11	-0.03	-0.11	-0.05	0.11	-0.01	-0.06	0.18* 0.69*

Table 6
Determinants of Contract Length

	Length of Contract		
	(1)	(2)	(3)
Meeting Frequency	0.075 (0.25)	0.925 (2.54)*	1.458 (2.11)*
Board Seat Allocated?	-1.650 (0.60)		
Equity	-1.690 (0.79)	-1.217 (0.55)	-3.513 (1.49)
Equity Stake	0.659 (3.03)**	0.560 (3.36)**	0.488 (3.62)**
Firm Value		0.019 (1.78)	0.026 (2.07)*
Publicly Traded		-0.263 (0.13)	-1.604 (0.65)
Upfront Dummy			0.292 (0.15)
Upfront Amount			0.696 (2.43)*
Constant	18.526 (10.78)**	13.006 (6.05)**	11.635 (4.26)**
Observations	99	72	55
R-squared	0.19	0.37	0.48

Robust t statistics in parentheses

* significant at 5%; ** significant at 1%